Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Pazopanib |
Synonyms | |
Therapy Description |
Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pazopanib | Votrient | GW-786034 | FGFR1 Inhibitor 23 FGFR2 Inhibitor 16 FGFR3 Inhibitor 12 KIT Inhibitor 51 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 32 | Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | uterus leiomyosarcoma | not applicable | Pazopanib | Clinical Study | Actionable | In a retrospective clinical study, 33% (9/27) of patients with uterine leiomyosarcoma responded to Votrient (pazopanib) treatment (PMID: 29185261). | 29185261 |
FGFR3 R248C | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770). | 23786770 |
Unknown unknown | liposarcoma | not applicable | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 8 weeks and median survival of 7.3 months in patients with liposarcoma (PMID: 26970174). | 26970174 |
Unknown unknown | lung non-small cell carcinoma | not applicable | Pazopanib | Phase II | Actionable | In a Phase II trial, Votrient (pazopanib) treatment resulted in 86% (30/35) of patients with non-small cell lung cancer experiencing a decrease in tumor size, including one patient with a greater than 50% reduction, and resulted in a partial response based on RECIST criteria in three patients (PMID: 20516450). | 20516450 |
Unknown unknown | germ cell cancer | not applicable | Pazopanib | Phase II | Actionable | In a Phase II trial, Votrient (pazopanib) treatment resulted in partial responses in 4.7% (2/43), stable disease in 44.2% (19/43), and a 3-month progression free survival probability of 12.8% in patients with refractory germ cell cancer (PMID: 28383677). | 28383677 |
FGFR1 amp | Her2-receptor negative breast cancer | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring FGFR1 amplification demonstrated antitumor activity when treated with Votrient (pazopanib), including a near complete loss of brain lesions and improved function of the liver (PMID: 29223982). | 29223982 |
Unknown unknown | fibrous histiocytoma | not applicable | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 15.3 weeks and median survival of 9.5 months in patients with undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (PMID: 26970174). | 26970174 |
Unknown unknown | breast cancer | not applicable | Pazopanib | Phase II | Actionable | In a Phase II trial, Votrient (pazopanib) displayed safety and some efficacy in breast cancer patients (PMID: 20682606). | 20682606 |
FGFR3 S249C | renal pelvis transitional cell carcinoma | predicted - sensitive | Pazopanib | Clinical Study | Actionable | In a case study, a patient with urothelial carcinoma of the renal pelvis harboring FGFR3 S249C demonstrated a partial response lasting 9 months following treatment with Votrient (pazopanib) (PMID: 27271022). | 27271022 |
Unknown unknown | clear cell renal cell carcinoma | not applicable | Pazopanib | Phase III | Actionable | In a Phase III trial, Votrient (pazopanib) did not result in a significantly improved disease free survival compared to placebo in patients with renal clear cell carcinoma (PMID: 28902533). | 28902533 |
Unknown unknown | clear cell renal cell carcinoma | not applicable | Pazopanib | Phase II | Actionable | In a Phase II trial, 84% (84/100) of patients with renal clear cell cancer demonstrated a clinical benefit, which included a median tumor reduction of 14.4%, when treated with Votrient (pazopanib) prior to a planned nephrectomy (PMID: 27254750). | 27254750 |
FGFR2 K660N | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770). | 23786770 |
NRAS mutant | acute myeloid leukemia | predicted - resistant | Pazopanib | Preclinical - Patient cell culture | Actionable | In a preclinical study, NRAS mutations correlated with resistance to Votrient (pazopanib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627). | 30333627 |
FGFR2 P253R | head and neck squamous cell carcinoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Votrient (pazopanib) resulted in reduced tumor size in a patient with head and neck squamous cell carcinoma harboring FGFR2 P253R (PMID: 23786770). | 23786770 |
PDGFRA amp | pleomorphic liposarcoma | sensitive | Pazopanib | Preclinical - Pdx | Actionable | In a preclinical study, Votrient (pazopanib) treatment induced necrosis and reduced tumor growth in an Adriamycin (doxorubicin)-resistant orthotopic patient-derived xenograft (PDX) model of pleomorphic liposarcoma harboring PDGFRA amplification (PMID: 30060824). | 30060824 |
FGFR3 - BAIAP2L1 | urinary bladder cancer | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, bladder cancer cells harboring FGFR3-BAIAP2L1 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953). | 23558953 |
Unknown unknown | renal cell carcinoma | not applicable | Pazopanib | Phase III | Actionable | In a Phase III trial, adjuvant Votrient (pazopanib) therapy post nephrectomy did not improve disease-free survival (HR=0.862, p=0.165) compared to placebo in patients with renal cell carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 4507)). | detail... |
Unknown unknown | renal cell carcinoma | not applicable | Pazopanib | FDA approved | Actionable | In a Phase III trial that supported FDA approval, Votrient (pazopanib) improved progression free survival in patients with advanced renal cell carcinoma (PMID: 20100962). | 20100962 detail... |
Unknown unknown | sarcoma | not applicable | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 15.4 weeks and median survival of 11.2 months in patients with soft tissue sarcoma (PMID: 26970174). | 26970174 |
Unknown unknown | sarcoma | not applicable | Pazopanib | FDA approved | Actionable | In a Phase III trial that supported FDA approval, Votrient (pazopanib) improved progression free survival in patients with advanced soft tissue sarcoma (PMID: 22595799). | 22595799 detail... |
Unknown unknown | synovial sarcoma | not applicable | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 16.4 weeks and median survival of 10.6 months in patients with synovial sarcoma (PMID: 26970174). | 26970174 |
Unknown unknown | gastrointestinal neuroendocrine tumor | not applicable | Pazopanib | Clinical Study | Actionable | In a clinical study, Votrient (pazopanib) treatment in patients with gastroenteropancreatic neuroendocrine tumors resulted in an overall response rate of 24% (19/124), stable disease in 39.5% (49/124), a progression free survival of 36% at six months, and a median overall survival of 10.2 months (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 446P). | detail... |
Unknown unknown | Advanced Solid Tumor | not applicable | Pazopanib | Phase I | Actionable | In a Phase I trial, Votrient (pazopanib) demonstrated safety and efficacy in a variety of pediatric solid tumors (PMID: 23857966). | 23857966 |
Unknown unknown | Advanced Solid Tumor | not applicable | Pazopanib | Phase I | Actionable | In a Phase I study, Votrient (pazopanib) in combination with Taxol (paclitaxel) and Paraplatin (carboplatin) demonstrated efficacy in solid tumors (PMID: 22679111). | 22679111 |
FGFR3 - TACC3 | urinary bladder cancer | sensitive | Pazopanib | Preclinical | Actionable | In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953). | 23558953 |
Unknown unknown | leiomyosarcoma | not applicable | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 18.6 weeks and median survival of 20.1 months in patients with leiomyosarcoma (PMID: 26970174). | 26970174 |
Unknown unknown | uterine corpus sarcoma | not applicable | Pazopanib | Clinical Study | Actionable | In a retrospective clinical study, Votrient (pazopanib) treatment resulted in objective response in 29% (10/35) and stable disease in 31% (11/35) of patients with uterine sarcoma, with median progression-free survival of 5.8 months and overall survival of 20.0 months (PMID: 29185261). | 29185261 |
FGFR2 K660E | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770). | 23786770 |
Unknown unknown | gastrointestinal stromal tumor | not applicable | Pazopanib | Phase II | Actionable | In a Phase II trial, treatment with Votrient (pazopanib) plus best supportive care (BSC) resulted in improved progression-free survival (45% at 4 months) compared to BSC alone (15% at 4 months) in patients with Gleevec (imatinib) and Sutent (sunitinib)-resistant gastrointestinal stromal tumors (J Clin Oncol 33, 2015 (suppl; abstr 10506)). | detail... |
FGFR2 W290C | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770). | 23786770 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02180867 | Phase II | Pazopanib Doxorubicin + Ifosfamide | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS) | Active, not recruiting | USA | CAN | 1 |
NCT02049905 | Phase III | Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Completed | USA | CAN | 11 |
NCT01217931 | Phase II | Everolimus Pazopanib Bevacizumab | Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy | Active, not recruiting | USA | 0 |
NCT01759303 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | Terminated | USA | 0 |
NCT01407562 | Phase I | Carboplatin Paclitaxel Pazopanib | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT01767636 | Phase II | Pazopanib | Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer | Active, not recruiting | USA | 0 |
NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Active, not recruiting | USA | 0 |
NCT01330966 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma | Completed | USA | 1 |
NCT02014636 | Phase I | Pazopanib Pembrolizumab | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) | Completed | USA | 1 |
NCT01236547 | Phase II | Paclitaxel Pazopanib | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT01575548 | Phase III | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Active, not recruiting | USA | 0 |
NCT02601209 | Phase Ib/II | Pazopanib Sapanisertib | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT01468922 | Phase I | Tivantinib Pazopanib | Pazopanib and ARQ 197 for Advanced Solid Tumors | Completed | USA | 0 |
NCT02406521 | Phase I | Pazopanib Radium Ra 223 dichloride Sorafenib | Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases | Completed | USA | 0 |
NCT02956798 | Phase II | Pazopanib | Pazopanib Vs. Local Therapy for Renal Cancer With Metastases | Active, not recruiting | USA | 0 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02729194 | Phase I | Pazopanib | Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | Completed | USA | 0 |
NCT03334409 | Phase II | Pazopanib | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT01599832 | Phase I | Pazopanib | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | Terminated | USA | 0 |
NCT01506596 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | Completed | USA | 0 |
NCT02560012 | Phase II | Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Terminated | USA | 0 |
NCT01339871 | Phase I | Vorinostat Pazopanib | Phase I Study of Pazopanib and Vorinostat | Completed | USA | 0 |
NCT01466972 | Phase II | Pazopanib | Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib | Completed | USA | 0 |
NCT01221506 | Phase I | Pazopanib | Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT02307474 | Phase I | Pazopanib | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | Withdrawn | USA | 0 |
NCT01392183 | Phase II | Diphenhydramine Temsirolimus Pazopanib | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT02979899 | Phase III | Pazopanib Carotuximab + Pazopanib | A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS) | Completed | USA | 7 |
NCT01158521 | Phase II | Pazopanib | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | Completed | USA | 0 |
NCT01462630 | Phase II | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | Active, not recruiting | USA | 0 |
NCT01956669 | Phase II | Pazopanib | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | Completed | USA | CAN | 5 |
NCT01832259 | Phase II | Pazopanib | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | Completed | USA | 0 |
NCT03592472 | Phase III | Pazopanib Abexinostat + Pazopanib | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Active, not recruiting | USA | 4 |
NCT01361113 | Phase II | Pazopanib | Neoadjuvant Pazopanib in Renal Cell Carcinoma | Completed | USA | 0 |
NCT04199026 | Phase I | Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | Not yet recruiting | USA | 0 |
NCT01552356 | Phase I | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT02193152 | Phase I | Pazopanib | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Terminated | USA | 0 |
NCT01841736 | Phase II | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02300545 | Phase II | Pazopanib | Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | Completed | USA | 0 |
NCT01582204 | Phase I | Pazopanib Sunitinib | Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03200717 | Phase II | Pazopanib | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment | Active, not recruiting | USA | CAN | 9 |